Antimicrobial susceptibility of 840 clinical isolates of Haemophilus influenzae collected in four European countries in 2000-2001.
In 2000-2001, 840 clinical isolates of Haemophilus influenzae were collected from laboratories in France, Germany, Italy and Spain (210 isolates/country). Beta-Lactamase production among the isolates varied considerably by country, ranging from 8.1% in Germany to 34.8% in France. H. influenzae from patients <or=4 years old showed the highest prevalence of beta-lactamase production (23.2%), compared with isolates from patients aged 5-17 years (17.8%) and >or=18 years (16.5%). All isolates were susceptible to amoxicillin-clavulanate, ciprofloxacin and levofloxacin; 99.6% and 98.9% of isolates were susceptible to azithromycin and cefuroxime, respectively. Among the macrolides tested, azithromycin (MIC90, 2 mg/L) was eight-fold more potent than clarithromycin (MIC90, 16 mg/L) and roxithromycin (MIC90, 16 mg/L). Despite variations in beta-lactamase production between different countries, > 99% of all isolates were susceptible to amoxicillin-clavulanate, ciprofloxacin, levofloxacin, and azithromycin.
Blosser-Middleton
R
R
Focus Technologies, 13665 Dulles Technology Drive, Suite 200, Herndon, VA 20171, USA.
Sahm
D F
DF
Thornsberry
C
C
Jones
M E
ME
Hogan
P A
PA
Critchley
I A
IA
Karlowsky
J A
JA
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D005060:Europe / Q000453:epidemiology; D006192:Haemophilus Infections / Q000175:diagnosis; D006193:Haemophilus influenzae / Q000187:drug effects* / Q000201:enzymology / Q000302:isolation & purification; D006801:Humans; D008826:Microbial Sensitivity Tests; D011446:Prospective Studies; D001618:beta-Lactamases / Q000096:biosynthesis
D000900:Anti-Bacterial Agents; D001618:beta-Lactamases